Komori
Share Issuance and Disposal4882Perseus Proteomics Inc.Pharmaceuticals

Explanation of the Financing

The document explains a plan to raise ¥459 million in total by issuing the 31st Series Stock Acquisition Rights to fund research and development and working capital. It supplements the terms and use of the financing, along with its anticipated advantages and disadvantages, rather than presenting corrections.

Worth reading
0Immaterial
Scored from 2 of 3 sections
Direction
Neutral
Direction inferred from the company’s description.
Scale
459
million yen
Wording
Avoiding a definitive answer
How definitive the wording is.

What was corrected and how

A subsequent correction by the company to the contents of an already published filing.

Original disclosure
The number of days elapsed cannot be calculated because the original disclosure date is unknown.
This correction2026-11-20
What was corrected and how
ItemDetails
Items this document does not state (6)
Disclosure subject to correctionOriginal disclosure dateLocation of correctionDetails of correctionReason for correctionImpact on Business Performance

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

To create new pipelines following those currently under out-licensing activities, which is necessary to achieve sustainable growth in the pharmaceutical business, and to apply the funds to research and development and working capital.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.